-Reuters
This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout
Raymond James downgraded PolyPid Ltd (NASDAQ:PYPD) from Strong Buy to Outperform post SHIELD I Phase 3 results that, despite consistency and evidence of…
Related Posts
Eastman Kodak Company Granted U.S. Patent #11535935: Deposition system with vacuum pre-loaded deposition head
https://www.scribd.com/document/616553020/KODK-Patent
Digital Or Physical Stores? – The Answer Is Both, Says This Analyst Looking On Retail Real Estate Trends
Telsey Advisory Group analyst Dana Telsey said physical stores remain the greatest source of new customer acquisition for most consumer companies.
And, the pandemic removed the pre-pandemic conversation of “either or” between digital and physical channels, noted the analyst.
Wall Street’s Most Accurate Analysts Say Buy These 3 Energy Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.